Medical Health & Life Science Research News

Research report explores the global endometrial cancer drugs pipeline therapeutics review

Endometrial Cancer vaccine Pipeline Review H1 2017 report provides comprehensive information on the therapeutics under development for Endometrial Cancer vaccine, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.The report reviews key players involved Endometrial Cancer therapeutics and enlists all their major and minor projects

- Agency -.

Endometrial Cancer Pipeline Review H1 2017 report provides comprehensive information on the therapeutics under development for Endometrial Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Additionally, the report provides an overview of key players involved in therapeutic development for Endometrial Cancer and features dormant and discontinued projects. Endometrial cancer is cancer that starts in the endometrium, the lining of the uterus (womb).

- Agency -.

Endometrial cancer is the most common type of uterine cancer.

Report: www.reportsnreports.com/contacts/.aspx?name=1057911

Description of Report:

Endometrial Cancer Pipeline Review H1 2017 report features investigational drugs from across globe covering therapy areas and indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The report provides a snapshot of the global therapeutic landscape of Endometrial Cancer

Key Companies Analyzed In Report:

AbbVie Inc, Ability Pharmaceuticals SL, Advenchen Laboratories LLC, Aeterna Zentaris Inc, ArQule Inc, Arrien Pharmaceuticals LLC, AstraZeneca Plc, AVEO Pharmaceuticals Inc, Bayer AG, BeiGene (Beijing) Co Ltd, BioNTech AG, Biscayne Pharmaceuticals Inc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, CBT Pharmaceuticals Inc, Cellceutix Corp, Critical Outcome Technologies Inc, CytomX Therapeutics Inc, Eisai Co Ltd, Eli Lilly and Company, Endocyte Inc, Esperance Pharmaceuticals Inc, Exelixis Inc, F. Hoffmann-La Roche Ltd, Galena Biopharma Inc, GamaMabs Pharma SA, Genmab A/S, GlaxoSmithKline Plc, Glycotope GmbH, Gradalis Inc, Horizon Pharma Plc, Immunocore Ltd, ImmunoGen Inc, Immunomedics Inc, Incyte Corp, Karyopharm Therapeutics Inc, Lion Biotechnologies Inc, MedImmune LLC, Merck & Co Inc, Merck KGaA, Merrimack Pharmaceuticals Inc, Merus NV, Millennium Pharmaceuticals Inc, Novartis AG, Pfizer Inc, Pharma Mar SA, Pivot Pharmaceuticals Inc, Puma Biotechnology Inc, Sanofi, Shenogen Pharma Group Ltd, Sigma-Tau SpA, Syndax Pharmaceuticals Inc, Synthon Holdings BV.

The report reviews pipeline therapeutics for Endometrial Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources. The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages.

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities. The report reviews key player’s involved Endometrial Cancer therapeutics and enlists all their major and minor projects.

The report assesses Endometrial Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report summarizes all the dormant and discontinued pipeline projects.

The report reviews latest news related to pipeline therapeutics for Endometrial Cancer

Report: www.reportsnreports.com/contacts/.aspx?name=1057911

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies. Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Identify and understand important and diverse types of therapeutics under development for Endometrial Cancer. Identify potential new clients or partners in the target demographic.

Develop strategic initiatives by understanding the focus areas of leading companies. Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics.

Devise corrective measures for pipeline projects by understanding Endometrial Cancer pipeline depth and focus of Indication therapeutics. Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Major Table OF Content

  • Number of Products under Development for Endometrial Cancer, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017 30
  • Number of Products by Stage and Mechanism of Action, H1 2017 31
  • Number of Products by Stage and Route of Administration, H1 2017 33
  • Number of Products by Stage and Molecule Type, H1 2017 35
  • Endometrial Cancer - Dormant Projects, H1 2017 50
  • Endometrial Cancer - Pipeline by AbbVie Inc, H1 2017
  • Endometrial Cancer - Pipeline by Ability Pharmaceuticals SL, H1 2017
  • Endometrial Cancer - Pipeline by Advenchen Laboratories LLC, H1 2017
  • Endometrial Cancer - Pipeline by Aeterna Zentaris Inc, H1 2017
  • Endometrial Cancer - Pipeline by ArQule Inc, H1 2017
  • Endometrial Cancer - Pipeline by Arrien Pharmaceuticals LLC, H1 2017
  • Endometrial Cancer - Pipeline by AstraZeneca Plc, H1 2017
  • Endometrial Cancer - Pipeline by AVEO Pharmaceuticals Inc, H1 2017
  • Endometrial Cancer - Pipeline by Bayer AG, H1 2017
  • Endometrial Cancer - Pipeline by BeiGene (Beijing) Co Ltd, H1 2017
  • Endometrial Cancer - Pipeline by BioNTech AG, H1 2017
  • Endometrial Cancer - Pipeline by Biscayne Pharmaceuticals Inc, H1 2017
  • Endometrial Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2017
  • Endometrial Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2017
  • Endometrial Cancer - Pipeline by CBT Pharmaceuticals Inc, H1 2017
  • Endometrial Cancer - Pipeline by Cellceutix Corp, H1 2017
  • Endometrial Cancer - Pipeline by Critical Outcome Technologies Inc, H1 2017
  • Endometrial Cancer - Pipeline by CytomX Therapeutics Inc, H1 2017
  • Endometrial Cancer - Pipeline by Eisai Co Ltd, H1 2017
  • Endometrial Cancer - Pipeline by Eli Lilly and Company, H1 2017

Report: www.reportsnreports.com/.aspx?name=1057911

 

News From

ReportsnReports - Industry Trends & ForecastsReportsnReports
Category: Market Research Publishers and RetailersCompany profile: ReportsnReports.com provides market research reports to industries, individuals and organizations with an objective of helping them in their decision-making process. Our library of 400,000+ industry & country research reports covers 5000+ micro markets.